Dr. Silver received the award in recognition of his contributions to international integration of research in the field of leukemia.
A premier investigator in the areas of translational and clinical drug development, Dr. Hidalgo has been at the helm of the early clinical development of more than 50 new anticancer agents.
Pembrolizumab was administered to patients who had already undergone extensive chemotherapy for advanced esophageal cancer and who, subsequently, had not responded to any other treatment.
This therapy is primarily being studied for resistant prostate cancer that has spread and/or has not responded to hormonal therapy.
A preeminent hematologist, neuroscientist, administrator, and educator, Dr. Hempstead’s distinguished career at Weill Cornell has spanned more than 30 years.
Dr. Faltas's study, entitled “APOBEC mutagenesis in bladder cancer: mechanisms and therapeutic opportunities,” will receive $840,000 over two years.
His outstanding operational and leadership skills will be utilized in his new role, in which he will advance key educational and academic activities as well as other areas of importance to the department.
Initiated in 2002, the award is given to fellows within the Weill Department of Medicine who have performed outstanding research. This year's finalists were presented at Medicine Grand Rounds on June 20.
The Pershing Square Foundation supports young investigators who demonstrate creativity, passion, and an ability to think unconventionally while exploring new territory in research to discover cures for cancer.
Dr. Ferrarone will receive a four-year award in the amount of $460,000 to support his research activities in the area of lung adenocarcinoma, which is the most common form of lung cancer.
